carmustine has been researched along with Central Nervous System Diseases in 8 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Central Nervous System Diseases: Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the effect of a reduced dose of radiotherapy (RT) in patients with primary CNS lymphoma (PCNSL) responding to the cyclophosphamide, doxorubicin, vincristine, and dexamethasone (CHOD)/carmustine, vincristine, methotrexate, and cytarabine (BVAM) regimen." | 5.10 | Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. ( Bessell, EM; Byrne, P; Graus, F; López-Guillermo, A; Montserrat, E; Nomdedeu, B; Petit, J; Verger, E; Villá, S, 2002) |
| "High-dose chemotherapy with BCNU, melphalan, or both, followed by autologous bone marrow transplantation (ABMT) has been reported to produce response rates in excess of 60% in patients with advanced melanoma." | 3.67 | High-dose chemotherapy without autologous bone marrow transplantation in melanoma. ( Aisner, J; Tait, N; Tchekmedyian, NS; Van Echo, D, 1986) |
| "The incidence of brain metastases was neither lowered nor delayed by the presence of BCNU in regimens A and C." | 2.64 | Comparative evaluation of three combination regimens for advanced malignant melanoma: results of an international cooperative study. ( Beretta, G; Bonadonna, G; Cascinelli, N; Morabito, A; Veronesi, U, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (87.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grimson, BS | 1 |
| Mahaley, MS | 1 |
| Dubey, HD | 1 |
| Dudka, L | 1 |
| Phillips, GL | 1 |
| Fay, JW | 1 |
| Herzig, GP | 1 |
| Herzig, RH | 1 |
| Weiner, RS | 1 |
| Wolff, SN | 1 |
| Lazarus, HM | 1 |
| Karanes, C | 1 |
| Ross, WE | 1 |
| Kramer, BS | 1 |
| Torrey, JJ | 1 |
| Katakkar, SB | 1 |
| Bessell, EM | 1 |
| López-Guillermo, A | 1 |
| Villá, S | 1 |
| Verger, E | 1 |
| Nomdedeu, B | 1 |
| Petit, J | 1 |
| Byrne, P | 1 |
| Montserrat, E | 1 |
| Graus, F | 1 |
| Murphy, SG | 1 |
| LoBuglio, AF | 1 |
| Beretta, G | 1 |
| Bonadonna, G | 1 |
| Cascinelli, N | 1 |
| Morabito, A | 1 |
| Veronesi, U | 1 |
| Lynch, RG | 1 |
| Medoff, G | 1 |
| Valeriote, F | 1 |
| Tchekmedyian, NS | 1 |
| Tait, N | 1 |
| Van Echo, D | 1 |
| Aisner, J | 1 |
2 trials available for carmustine and Central Nervous System Diseases
| Article | Year |
|---|---|
Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central | 2002 |
Comparative evaluation of three combination regimens for advanced malignant melanoma: results of an international cooperative study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Central Nervous System | 1976 |
6 other studies available for carmustine and Central Nervous System Diseases
| Article | Year |
|---|---|
Ophthalmic and central nervous system complications following intracarotid BCNU (Carmustine).
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Carotid Arteries; Central Nervous System Diseases; | 1981 |
Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.
Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Central Nervous S | 1983 |
Treatable meningeal involvement in Waldenström's macroglobulinemia.
Topics: Aged; Carmustine; Central Nervous System Diseases; Drug Therapy, Combination; Female; Humans; Immuno | 1984 |
L2C leukemia: a model of human acute leukemia.
Topics: Age Factors; Animals; BCG Vaccine; Carmustine; Central Nervous System Diseases; Cerebral Ventricle N | 1977 |
A murine model for central nervous system leukemia and its possible relevance to human leukemia.
Topics: Amphotericin B; Animals; Brain; Carmustine; Central Nervous System Diseases; Disease Models, Animal; | 1975 |
High-dose chemotherapy without autologous bone marrow transplantation in melanoma.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Di | 1986 |